Literature DB >> 10582681

A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.

N Suh1, Y Wang, C R Williams, R Risingsong, T Gilmer, T M Willson, M B Sporn.   

Abstract

We have tested a new ligand for peroxisome proliferator-activated receptor-gamma, GW7845, as an inhibitor of experimental mammary carcinogenesis, using the classic rat model with nitrosomethylurea as carcinogen. Rats were first treated with a single dose of nitrosomethylurea (50 mg/kg body weight, i.p.). Starting 1 week later, they were fed GW7845, at either 60 or 30 mg/kg of diet, for 2 months. This agent significantly reduced tumor incidence, tumor number, and tumor weight at both doses. This is the first report of the use of a ligand for peroxisome proliferator-activated receptor-gamma to prevent experimental breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582681

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Genetic variation in peroxisome proliferator-activated receptor gamma, soy, and mammographic density in Singapore Chinese women.

Authors:  Eunjung Lee; Chris Hsu; David Van den Berg; Giske Ursin; Woon-Puay Koh; Jian-Min Yuan; Daniel O Stram; Mimi C Yu; Anna H Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-01       Impact factor: 4.254

3.  Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Authors:  Hongyan Yuan; Geeta Upadhyay; Yuzhi Yin; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-28

4.  PPARgamma activation induces autophagy in breast cancer cells.

Authors:  Jie Zhou; Wei Zhang; Bing Liang; Mathew C Casimiro; Diana Whitaker-Menezes; Min Wang; Michael P Lisanti; Susan Lanza-Jacoby; Richard G Pestell; Chenguang Wang
Journal:  Int J Biochem Cell Biol       Date:  2009-06-26       Impact factor: 5.085

5.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

6.  Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Authors:  Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.

Authors:  Lifeng Tian; Jie Zhou; Mathew C Casimiro; Bing Liang; John O Ojeifo; Min Wang; Terry Hyslop; Chenguang Wang; Richard G Pestell
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

8.  Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

Authors:  B Chopra; N T Georgopoulos; A Nicholl; J Hinley; M B Oleksiewicz; J Southgate
Journal:  Cell Prolif       Date:  2009-07-10       Impact factor: 6.831

9.  PPARγ agonists target aromatase via both PGE2 and BRCA1.

Authors:  Ofer Margalit; Dingzhi Wang; Raymond N Dubois
Journal:  Cancer Prev Res (Phila)       Date:  2012-10

10.  Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).

Authors:  Carmen Aceves; Pablo García-Solís; Omar Arroyo-Helguera; Laura Vega-Riveroll; Guadalupe Delgado; Brenda Anguiano
Journal:  Mol Cancer       Date:  2009-06-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.